Morgan Stanley Upgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $8
Morgan Stanley Upgrades Centessa Pharmaceuticals to Equal-Weight, Raises Price Target to $8
摩根士丹利將Centessa Pharmicals上調至同等權重，將目標股價提高至8美元
Morgan Stanley analyst Matthew Harrison upgrades Centessa Pharmaceuticals (NASDAQ:CNTA) from Underweight to Equal-Weight and raises the price target from $4 to $8.
摩根士丹利分析師馬修·哈裡森將Centessa PharmPharmticals(納斯達克股票代碼：CNTA)的評級從減持上調至持平，並將目標價從4美元上調至8美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。